Is the price fair?
What OGN's price assumes
Organon & Co. trades at 17.6× earnings against 27.4× for the median Drug Manufacturers - General name, cheaper than its own group.
17.6
Trailing P/E · Drug Manufacturers - General median 27.4 · cheaper than the typical name in its group
- Price / sales
- 0.26
Price / sales · as of 2026-Q1
- Free cash flow yield
- 16%
Free cash flow yield · Drug Manufacturers - General median 5.8%
- Growth the price implies
- −10%
Growth the price implies · The price pays for −10% free cash flow growth a year for a decade; the business has delivered +5.0% a year over the last three.
Details›
- Price / book2026-Q1
- 1.74
- EV / sales2026-Q1
- 1.46
- Healthcare median P/E362 names
- 31.5
- Drug Manufacturers - General median P/E16 names
- 27.4
- Free cash flow, trailing twelve months
- $567M
- Market capitalisation
- $3.53B
- 3-year revenue growth
- −0.22%
- 3-year free cash flow growth
- +5.0%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $3.62 |
| Its own P/E history, median | $4.25 |
| Its own P/E history, upper quartile | $4.82 |
| 52-week range | $5.69 – $13.77 |
| Today | $13.77 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - General
Ranks #16 of 16 by Smart Score